FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1878881880> ?p ?o ?g. }

• W1878881880 endingPage "15347" @default.
• W1878881880 startingPage "15332" @default.
• W1878881880 abstract "// Chetna Sharon 3 , Somesh Baranwal 3 , Nirmita J. Patel 1 , Daniel Rodriguez-Agudo 1,4 , William M. Pandak 1,4 , Adhip P. N. Majumdar 5 , Geoffrey Krystal 1,2,3 and Bhaumik B. Patel 1,2,3 1 Hunter Holmes McGuire VA Medical Center, Richmond, VA, USA 2 Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA 3 Division of Hematology, Oncology and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA 4 Department of Medicine, Division of Gastroenterology, Virginia Commonwealth University, Richmond, VA, USA 5 John D. Dingell VAMC, Detroit, MI, USA Correspondence to: Bhaumik B. Patel, email: // Keywords : cancer stem cells, insulin-like growth factor-1 receptor, mTOR, mevalonate pathway, isoprenoids Received : October 31, 2014 Accepted : March 06, 2015 Published : March 29, 2015 Abstract We observed a co-upregulation of the insulin-like growth factor receptor (IGF-1R)/AKT/mammalian target of rapamycin (mTOR) [InAT] axis and the mevalonate-isoprenoid biosynthesis (MIB) pathways in colorectal cancer stem cells (CSCs) in an unbiased approach. Hence, we hypothesized that the InAT axis might regulate the MIB pathway to govern colorectal CSCs growth. Stimulation (IGF-1) or inhibition (IGF-1R depletion and pharmacological inhibition of IGF-1R/mTOR) of the InAT axis produced induction or attenuation of CSC growth as well as expression of CSC markers and self-renewal factors respectively. Intriguingly, activation of the InAT axis (IGF-1) caused significant upregulation of the MIB pathway genes (both mRNA and protein); while its inhibition produced the opposite effects in colonospheres. More importantly, supplementation with dimethylallyl- and farnesyl-PP, MIB metabolites downstream of isopentenyl-diphosphate delta isomerase (IDI), but not mevalonate and isopentenyl-pp that are upstream of IDI, resulted in a near-complete reversal of the suppressive effect of the InAT axis inhibitors on CSCs growth. The latter findings suggest a specific regulation of the MIB pathway by the InAT axis distal to the target of statins that inhibit 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR). Effects of IGF-1R inhibition on colonic CSCs proliferation and the MIB pathway were confirmed in an ‘ in vivo ’ HCT-116 xenograft model. These observations establish a novel mechanistic link between the InAT axis that is commonly deregulated in colorectal cancer and the MIB pathway in regulation of colonic CSCs growth. Hence, the InAT-MIB corridor is a novel target for developing paradigm shifting optimum anti-CSCs therapies for colorectal cancer." @default.
• W1878881880 created "2016-06-24" @default.
• W1878881880 creator A5000793481 @default.
• W1878881880 creator A5020988215 @default.
• W1878881880 creator A5029214095 @default.
• W1878881880 creator A5036406250 @default.
• W1878881880 creator A5050495708 @default.
• W1878881880 creator A5054241961 @default.
• W1878881880 creator A5068291867 @default.
• W1878881880 creator A5090194700 @default.
• W1878881880 date "2015-03-29" @default.
• W1878881880 modified "2023-10-18" @default.
• W1878881880 title "Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway<i>in vitro</i>and<i>in vivo</i>" @default.
• W1878881880 cites W1585383225 @default.
• W1878881880 cites W1589421810 @default.
• W1878881880 cites W1842944210 @default.
• W1878881880 cites W1860242155 @default.
• W1878881880 cites W1968659767 @default.
• W1878881880 cites W1970005961 @default.
• W1878881880 cites W1983961550 @default.
• W1878881880 cites W1986789721 @default.
• W1878881880 cites W1987763783 @default.
• W1878881880 cites W1992059152 @default.
• W1878881880 cites W1996053472 @default.
• W1878881880 cites W2000302853 @default.
• W1878881880 cites W2004128874 @default.
• W1878881880 cites W2005864899 @default.
• W1878881880 cites W2009094422 @default.
• W1878881880 cites W2010160578 @default.
• W1878881880 cites W2025754007 @default.
• W1878881880 cites W2027049887 @default.
• W1878881880 cites W2028298372 @default.
• W1878881880 cites W2028663226 @default.
• W1878881880 cites W2035401368 @default.
• W1878881880 cites W2048945072 @default.
• W1878881880 cites W2060978652 @default.
• W1878881880 cites W2071124826 @default.
• W1878881880 cites W2073025161 @default.
• W1878881880 cites W2077073060 @default.
• W1878881880 cites W2081730209 @default.
• W1878881880 cites W2082472490 @default.
• W1878881880 cites W2085191274 @default.
• W1878881880 cites W2102085111 @default.
• W1878881880 cites W2105273528 @default.
• W1878881880 cites W2115602300 @default.
• W1878881880 cites W2119514671 @default.
• W1878881880 cites W2121215375 @default.
• W1878881880 cites W2126005618 @default.
• W1878881880 cites W2127617517 @default.
• W1878881880 cites W2131058993 @default.
• W1878881880 cites W2132063594 @default.
• W1878881880 cites W2148096512 @default.
• W1878881880 cites W2150144117 @default.
• W1878881880 cites W2161109457 @default.
• W1878881880 cites W2167553081 @default.
• W1878881880 cites W2168605114 @default.
• W1878881880 cites W2262414037 @default.
• W1878881880 cites W3021909102 @default.
• W1878881880 cites W901978 @default.
• W1878881880 doi "https://doi.org/10.18632/oncotarget.3684" @default.
• W1878881880 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4558155" @default.
• W1878881880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25895029" @default.
• W1878881880 hasPublicationYear "2015" @default.
• W1878881880 type Work @default.
• W1878881880 sameAs 1878881880 @default.
• W1878881880 citedByCount "23" @default.
• W1878881880 countsByYear W18788818802015 @default.
• W1878881880 countsByYear W18788818802016 @default.
• W1878881880 countsByYear W18788818802017 @default.
• W1878881880 countsByYear W18788818802019 @default.
• W1878881880 countsByYear W18788818802021 @default.
• W1878881880 countsByYear W18788818802022 @default.
• W1878881880 countsByYear W18788818802023 @default.
• W1878881880 crossrefType "journal-article" @default.
• W1878881880 hasAuthorship W1878881880A5000793481 @default.
• W1878881880 hasAuthorship W1878881880A5020988215 @default.
• W1878881880 hasAuthorship W1878881880A5029214095 @default.
• W1878881880 hasAuthorship W1878881880A5036406250 @default.
• W1878881880 hasAuthorship W1878881880A5050495708 @default.
• W1878881880 hasAuthorship W1878881880A5054241961 @default.
• W1878881880 hasAuthorship W1878881880A5068291867 @default.
• W1878881880 hasAuthorship W1878881880A5090194700 @default.
• W1878881880 hasBestOaLocation W18788818801 @default.
• W1878881880 hasConcept C104317684 @default.
• W1878881880 hasConcept C121608353 @default.
• W1878881880 hasConcept C126322002 @default.
• W1878881880 hasConcept C127561419 @default.
• W1878881880 hasConcept C134018914 @default.
• W1878881880 hasConcept C170493617 @default.
• W1878881880 hasConcept C2775960820 @default.
• W1878881880 hasConcept C2780689927 @default.
• W1878881880 hasConcept C502942594 @default.
• W1878881880 hasConcept C55427017 @default.
• W1878881880 hasConcept C55493867 @default.
• W1878881880 hasConcept C62478195 @default.
• W1878881880 hasConcept C71924100 @default.
• W1878881880 hasConcept C75217442 @default.
• W1878881880 hasConcept C86554907 @default.

• next